Top Markets
Coin of the day
Scilex Holding Company Scilex Holding Company

Scilex Holding Company

SCLX
株式のランク #25627
Scilex Holding Company is a biopharmaceutical enterprise that specializes in... Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
株価
$5.61
最終同期: 2026-08-20
時価総額
$47.65M
変化(1日)
-0.68%
変化(1年)
-67.26%
US
取引 Scilex Holding Company (SCLX)

カテゴリー

Scilex Holding Company(SCLX)のP/B比率
2026 時点のP/B比率 TTM: 0
Scilex Holding Company の最新の財務報告および株価によると、現在のP/B比率(TTM)は 0 です。2026 年末時点でのP/B比率は 0 でした。
Scilex Holding Company の P/B 比率の履歴(2026 ~ 2026)
各年末時点のP/B比率
P/B比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/B比率
企業 P/B比率 P/B比率の差
31.0864 -
US
7.4766 -
US
-74.4354 -
US
8.4776 -
CH
8.008 -
US